Incyte Corp. closed 18.70% short of its 52-week high of $83.95, which the company achieved on November 8th.

Incyte Corp. closed 16.64% below its 52-week high of $83.95, which the company achieved on November 8th.

Incyte is gearing up to report its fiscal second-quarter earnings later this month, with analysts forecasting a sharp surge ...

Incyte Corporation (NASDAQ:INCY) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Bridgewater ...

In a regulatory filing on Monday, Sun Pharma announced that it has reached a settlement and licensing agreement with Incyte ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Sun Pharmaceutical Industries has reached a settlement agreement with Incyte Corporation concerning Leqselvi, a drug for ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Sun Pharma settles litigation with Incyte, gains license for alopecia treatment, launches LEQSELVI tablet in the US.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...